-+ 0.00%
-+ 0.00%
-+ 0.00%

First Berlin reiterates Buy on Valneva, cuts price target to EUR 4.5

PUBT·05/28/2026 15:08:49
Listen to the news
First Berlin reiterates Buy on Valneva, cuts price target to EUR 4.5
  • First Berlin reiterated a Buy on Valneva, cutting its 12-month price target to EUR 4.5 from EUR 4.8.
  • Q1 2026 product sales fell 37.2% to EUR 30.9 million, prompting a 7% cut to FY 2026 product sales guidance to EUR 135-150 million.
  • First Berlin flagged weakening travel vaccine demand in key markets, citing geopolitical tensions as a driver.
  • Investor focus remains on Pfizer’s planned BLA filing for Lyme disease vaccine candidate LB6V in H2 2026.
  • First Berlin put FDA approval odds for LB6V at 67%, citing the upcoming pre-filing FDA meeting and the expected Day 74 letter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valneva SE published the original content used to generate this news brief via EQS News (Ref. ID: rc_25912) on May 28, 2026, and is solely responsible for the information contained therein.